Assessment of Impact on Management by Zircaix PET/CT (AIMZ PET/CT)

This is a prospective, non-randomised study involving patients who will be identified by managing clinicians and referred to the Melbourne Theranostic Innovation Centre for imaging on the Siemens Biograph Vision Quadra for suspected or proven CA-IX-expressing tumours. Patient selection will involve accruing 100 suitable patients into the following three groups: • Group 1: 30 patients with a presumed or suspected primary diagnosis of ccRCC based on conventional imaging with ultrasound, CT or MRI, including up to 10 individuals with VHL mutation • Group 2: 20 patients with a presumed or proven diagnosis of mesothelioma • Group 3: 50 patients evaluated in the post-treatment setting for evaluation of residual mass lesions or assessment of therapeutic response with either ccRCC or mesothelioma or other cancers anticipated to have elevated CA-IX expression The pretest management decision based on all other available information (treatment intention) will be recorded prior to the PET scan. The actual treatment performed will be reviewed at 6 and 12 months after the scan. The accuracy of the PET scan will be ascertained from the results of other imaging studies, pathological and surgical findings and from clinical outcome including survival. Other correlative imaging studies performed within 2 weeks of the PET and without intervening procedures or treatment that may impact comparability of the scans, will be directly compared with the PET scan to assess the accuracy with which tumour detection is achieved by each modality.